Trial Profile
A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 14 Nov 2023
Price :
$35
*
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Lymphoma
- Focus Expanded access; Therapeutic Use
- Acronyms ZUMA-9
- Sponsors Kite Pharma
- 19 Mar 2021 Status changed from recruiting to completed.
- 08 Dec 2020 Results (n=25; Cohort 1 and n=36; Cohort 2) reporting safety and efficacy outcomes from this expanded access study presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 15 Jul 2020 Results of serum and tumor analysis from 75 patients treated in tis study published in the Clinical Cancer Research.